Regeneron Pharma stock (US75886F1075): Biotech leader in eye and oncology treatments

Regeneron Pharmaceuticals, a leading biotechnology company, focuses on developing treatments for serious diseases through genetic and protein engineering. The company reported first-quarter 2026 revenue of $3.4 billion, up 8% from the prior year, driven by strong sales of Eylea and Dupixent, according to Regeneron Q1 2026 earnings as of May 5, 2026.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Regeneron Pharma: core business model

Regeneron Pharmaceuticals develops medicines for eye diseases, cancer, allergic and inflammatory conditions, and rare diseases. Its proprietary VelociSuite technologies, including VelocImmune, enable rapid antibody discovery. The company collaborates with Sanofi on Dupixent and partners with Bayer on Eylea, sharing profits in major markets. Regeneron reinvests heavily in R&D, with $1.1 billion spent in Q1 2026 for the three months ended March 31, 2026, per Regeneron Q1 2026 report as of May 5, 2026.

This model emphasizes high-margin monoclonal antibodies and gene therapies, positioning Regeneron as a key player in US biotech with exposure to the $500 billion global pharma market.

Main revenue and product drivers for Regeneron Pharma

Eylea, approved for wet age-related macular degeneration and diabetic macular edema, generated $1.5 billion in global net product sales in Q1 2026, a 5% increase year-over-year, according to the company's earnings release for the period ended March 31, 2026, published May 5, 2026. Higher-dose Eylea HD, launched in 2023, supports sustained demand in the US ophthalmology market.

Dupixent collaboration revenue reached $800 million in the quarter, up 15%, driven by expanded indications in asthma, eczema, and COPD. Oncology drugs like Libtayo added $250 million, reflecting growth in immuno-oncology. These drivers underscore Regeneron's relevance to US investors tracking biotech growth stocks on Nasdaq.

Industry trends and competitive position

The biotech sector faces patent cliffs and biosimilar competition, yet Regeneron's diversified portfolio mitigates risks. Eylea faces Roche's Vabysmo, but Regeneron's aflibercept 8 mg formulation shows durable efficacy in trials. In oncology, PD-1 inhibitors like Libtayo compete with Keytruda, per Reuters biotech update as of April 2026.

Regeneron's US headquarters and Nasdaq listing make it a core holding for investors eyeing domestic innovation leaders.

Why Regeneron Pharma matters for US investors

Listed on Nasdaq under REGN, Regeneron benefits from strong US reimbursement and a $100 billion+ domestic pharma spend. Its genetics platform, including the Regeneron Genetics Center sequencing over 2 million exomes, fuels pipeline discoveries relevant to precision medicine trends in the US healthcare system.

Recent financial performance

For full-year 2025, Regeneron posted $13.9 billion in total revenue, with net income of $4.1 billion, as detailed in its annual report published February 2026. Q1 2026 EPS came in at $7.23, beating consensus estimates, per the May 5 earnings call transcript on the IR site.

Conclusion

Regeneron Pharmaceuticals maintains robust revenue from established products while advancing its pipeline in oncology and rare diseases. US investors monitor its Nasdaq performance amid biotech volatility and regulatory shifts. The company's R&D focus positions it for long-term contributions to healthcare innovation.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.